Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAGON oral corticosteroid tapering study in adults with generalized myasthenia gravis treated with ravulizumab
2025-522555-26-00Phase 4Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of ravulizumab, prednisone and prednisolone in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Jun 2026; status: completed.
02
Drugs
ravulizumabprednisoneprednisolone
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2025-522555-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522555-26-00.